Targeting energy expenditure: the next wave of obesity drugs
In the wake of their seismic ascension over the lucrative weight loss market, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are facing…
All articles by Frankie Fattorini
Frankie Fattorini
Frankie Fattorini is a healthcare and pharmaceutical reporter. His background is in genomics research, and he has also worked in medical communications. Frankie has written freelance articles on emerging technologies and various pieces on oncology and drug development.
-
-
EU’s Pharma Package falls short of Europe’s goal of global competitiveness
In a bid to chase competitiveness, the EU is advancing its most drastic revision of pharmaceutical law in 20 years.…
-
ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study
Johnson & Johnson (J&J) has unveiled first-in-human data on its trispecific antibody that demonstrates a 100% response rate in a…
-
ASCO25: Kura’s Phase II ziftomenib results trigger NDA acceptance from FDA
A November 2025 PDUFA date has been set for Kura Oncology’s oral acute myeloid leukaemia (AML) drug ziftomenib following the…
-
ASCO25: Amgen’s Nplate proves effective in GI cancer-linked thrombocytopaenia
Amgen’s Nplate (romiplostim) has demonstrated efficacy in treating thrombocytopaenia among gastrointestinal (GI) cancer patients, as Phase III RECITE results are…
-
ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups
Updated analysis showed Carvykti (ciltacabtagene autoleucel) improved survival for multiple myeloma patients regardless of their cytogenetic risk or prior lines…
-
ASCO25: Pfizer’s Braftovi combo boasts 47% drop in disease progression in mCRC
Pfizer’s Braftovi (encorafenib) combination therapy was shown to reduce the risk of death by nearly half compared to standard of…
-
Capitalising on UK’s goal to become a world-leading clinical trial destination
Representatives of industry and regulation will meet in June to discuss paths forward for the UK’s clinical trials sector following…
-
Can pharma tariffs “Make America Manufacture Again”?
As President Trump continues to signal import tariffs on pharmaceuticals to bolster US manufacturing, experts warn this could hike costs…
-
Investors insist halted biotech IPOs will return in 2025
Investors remain optimistic for a return of biotech IPOs in 2025 despite a market downturn following the announcement of US…